Affordable Access

Publisher Website

Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas

Authors
Journal
BMC Biology
1741-7007
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
9
Issue
1
Identifiers
DOI: 10.1186/1741-7007-9-72
Keywords
  • Commentary
Disciplines
  • Biology
  • Medicine

Abstract

Current interest in proteasome inhibitors for cancer therapy has stimulated considerable research efforts to identify the molecular pathway to their cytotoxicity with a view to identifying the mechanisms of sensitivity and resistance as well as informing the development of new drugs. Zhao and Vuori describe this month in BMC Biology experiments indicating a novel role of the adaptor protein p130Cas in sensitivity to apoptosis induced not only by proteasome inhibitors but also by the unrelated drug doxorubicin. See research article: http:// http://www.biomedcentral.com/1741-7007/9/73

There are no comments yet on this publication. Be the first to share your thoughts.